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Purpose: To provide a literature review of implant related complications from bilateral 
  NewColorIris implantation (Kahn Medical Devices, Panama City, Panama).
Methods: A PubMed search of peer-reviewed ophthalmology journals for complications related 
to NewColorIris implants was performed.
Results: Including a recent case published by the authors, a total of nine patients (18 eyes) 
with management of complications such as endothelial cell loss, elevated intraocular pressure 
(IOP), corneal edema, anterior chamber inflammation, decreased visual acuity, and cataract 
formation were reviewed.
Conclusions: Sight-threatening complications including corneal decompensation, IOP 
  elevation, uveitis, and hyphema have been described after NewColorIris implantation.
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Introduction
For the purposes of cosmetic eye color change, NewColorIris (Kahn Medical Devices, 
Panama City, Panama) silicone prosthesis implants were developed in 2004.1 Although 
not approved by the Food and Drug Administration (FDA), implantation has been 
performed with subsequent complications noted in the literature, including endothelial 
cell loss, elevated intraocular pressure (IOP), corneal edema, anterior chamber 
  inflammation, decreased visual acuity, and cataract formation.2–8 While not specific to 
the NewColorIris, placement of phakic intraocular lenses have been associated with 
posterior segment complications, such as giant retinal tears.9
In recent years, NewColorIris implants have been removed following the 
  development of acute and chronic side effects.2–4,6–8,10 This paper summarizes the 
published cases of complications arising from NewColorIris implantation for cosmesis 
in phakic eyes.
Results
Table 1 was compiled from a PubMed search of peer-reviewed ophthalmology 
journals. To our knowledge, only eight cases (16 eyes) with complications following 
NewColorIris cosmetic implantation surgery had been published prior to the submission 
of our recent case.2–9 Of the nine known cases (18 eyes) including our own, six of the 
nine (66.7%) involve female patients. The only available long-term safety data comes 
from the manufacturer, which studied twelve female patients (24 eyes) with a mean 
endothelial cell density loss of 2.6% after eight months of follow-up.1 In this series, Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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only one patient (two eyes) required explantation due to 
uveitis and ocular hypertension. Our review summarizes 
nine cases (18 eyes), including one new bilateral case 
encountered by us that together suggest a need for more 
information regarding the long-term safety of NewColorIris 
implantation.
Symptomatic patients can be stratified into early 
(,1 month) or late (.6 months) symptom onset, with 
seven of nine cases (77.8%) presenting in the first 
postoperative month. Several of these patients reported 
immediate complications including hyphema, elevated 
intraocular pressure, and blurred vision.2,6 Others were 
asymptomatic in the immediate postoperative period, but 
developed complaints in the following weeks.4,5,8 The most 
common complaint amongst early and late presenters was 
decreased visual acuity/blurred vision, which was present 
in all nine patients (18 eyes, 100%). At last follow-up, 
nine of the 16 eyes (56.25%) had decreased best corrected 
visual acuity (BCVA), which is the same number of eyes 
with sub-optimal BCVA at presentation (Table 1).
In the early presentation cohort, only one of 14 eyes 
(7.1%) displayed hyphema, which resolved after anterior 
chamber paracentesis and two 25 mcg tissue plasmino-
gen activator (tPA) injections.2 A proportionately higher 
two of four eyes (50%) in the late presentation group 
developed hyphema, which resolved with conservative 
pharmacological management.3 Corneal edema and 
elevated intraocular pressure were more common find-
ings, occurring in 13 of 16 eyes (81.25%) and 12 of 16 
eyes (75%), respectively (Table 1). Exam findings were 
not available for one patient.7 All published cases indi-
cate anterior chamber inflammation visible by slit-lamp 
exam.
Several patients required surgery in addition to explan-
tation. These procedures included: three trabeculectomies 
for IOP management, two Descemet Stripping Automated 
Table 1 Cases of NewColoriris implantation for cosmesis
Source Age/sex/
implant  
color
Time to 
symptom 
onset
Eye Time to 
explantation
BCVA  
pre/post 
explantation
IOP (mmHg)  
at presentation/
peak/last  
follow-up
Endothelial  
cell density 
(cells/mm2)
Presence 
of corneal 
edema/
hyphema
Anderson  
et al2
27/F/green 2 weeks OD ∼3 weeks HM/20/60 44/44/12 206 +/+
OS .1 month 20/20/20/20 11/19/19 1292 NM/NM
40/F/green* 4 weeks OD – 20/20/CF 24/24/13 662 +/NM
OS – 20/25/20/40 14/14/8 1137 +/NM
Arthur  
et al3
29/M/green** 6 months OD ∼13 months 20/30/20/30 38/38/15 837 +/+
OS ∼13 months 20/70/20/150 40/40/10 1083 +/+
Castanera  
et al4
30/F/blue 1 week OD Not clear if  
explanted
20/160/20/125 36/36/16 N/A +/NM
OS ∼1 week CF/20/50 39/39/16 N/A +/NM
Hull  
et al6
27/F/blue 2 weeks OD 2–3 weeks 20/100/20/20 16/36/wnl 2476 +/NM
OS 2–3 weeks 20/40/20/16 32/42/wnl 2089 +/NM
Macdonald7 60/F/– 6 months OD – – – – +/NM
OS – – – – +/NM
Thiagalingam8 19/M/blue 13 days OD 5 weeks 20/40/20/20 19/50/17 1149 +/NM
OS 6 weeks 20/40+2/20/20 19/40/17 1353 +/NM
Garcia-Pous  
et al5
21/F/green 3 weeks OD – 20/60/- 30/30/“controlled” 1071 NM/NM
OS – 20/80/- 35/35/“controlled” 950 NM/NM
Sikder  
et al10
19/M/blue 1 week OD 4–5 months 20/20/20/25 14/16/12 – Absent/
absent
OS 4–5 months 20/20/2/25+2 14/14/15 – Absent/
absent
Notes: *Underwent LASiK OU 4 months prior to implants; **Patient became symptomatic after sustaining airbag trauma in a motor vehicle accident six months after 
surgery.
Abbreviations: BCVA, best corrected visual acuity; CF, counting fingers; HM, hand motion; IOP, intraocular pressure; NM, no mention of the corresponding exam finding; 
OD, right eye; OS, left eye; OU, both eyes. Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Endothelial Keratoplasties (DSAEK), and three peripheral 
iridotomies, two of which were performed by the implant 
surgeon.2,3,6,7 Hull et al, in their case report of a 27-year-old 
female who presented with a large peripheral iridotomy, 
  contended that their patient’s account of acute pain upon 
implantation suggests that the iridotomy was performed 
intraoperatively in response to iris-prolapse.6 Aside from 
the aforementioned procedures, one other patient was 
undergoing evaluation for Descemet’s stripping endothelial 
keratoplasty (DSEK) secondary to ongoing corneal edema 
at last follow-up.2
Discussion
In order to better understand the pathogenesis of the 
numerous complications seen in NewColorIris-implanted 
eyes, it is helpful to consider reported irregularities in the 
implants themselves. Several case reports in the litera-
ture identify manufacturing defects that likely contribute 
to implant dysfunction. In one such study, scanning electron 
microscope (SEM) images revealed surface irregularities 
and sharp edges that may contribute to the abrasion of the 
corneal endothelium and iris.4 Concerns about the implant’s 
peripheral footplates have also been documented.   According 
to the manufacturer, these footplates are responsible for 
minimizing the implant’s interaction with the trabecular 
meshwork.11 However, Anderson et al report that four 
of six footplates were missing from one of the explanted 
prostheses in their case report. They suspect that part of 
the implant had been hand-cut, resulting in significant edge 
irregularity.2 Several authors have also demonstrated a 
  tendency of the NewColorIris implant to directly contact the 
angle structures.3,4,8 Pentacam images of our patient similarly 
illustrate the implant’s close proximity to the iris and angle 
(Figure 1). These prostheses not only impinge on the angle 
structures, but shift position with time. Our patient displayed 
a temporally-shifted implant (Figure 2), while another case 
in the literature describes a nasally-decentered presentation. 
Other authors have published images   demonstrating 
improperly-sized implants that exhibit vaulting within the 
anterior chamber.2
The pathogenesis of the IOP increases commonly seen in 
these patients may be multifactorial. In light of microscopic 
images showing pigment-laden macrophages and direct 
pigment deposition on the surface of the implant, some 
authors have attributed the rise to iris pigment liberation.2,6,8 
Others have cited the implant’s direct contact with angle 
structures.2–4,6,8 Explantation is an effective means of 
controlling elevated IOP, but some patients may require 
long-term postoperative pharmacotherapy.2
In some cases, explanted eyes suffered insults that may 
lead to future complications. Our patient, like the one pre-
sented by Thiagalingam et al, developed bilateral prema-
ture sclerotic changes in his native lenses.8 A 30-year-old 
female described by Castanera et al experienced visual field 
deficits in her follow-up period.4 Other eyes were found 
to have significant corneal decompensation.2,3,5,8 Due to 
the high likelihood of postexplantation sequelae in these 
patients, they should receive long-term follow up with IOP, 
BCVA, endothelial cell counts, specular microscopy, and 
gonioscopy.
Steps should be taken to select appropriate candidates 
for artificial iris implantation. Currently, no criteria for 
candidacy have been established. While anterior chamber 
depth and baseline endothelial cell density should be 
evaluated, close attention must be given to the dimensions 
of the cornea at the limbus. Given the asymmetry of the 
horizontal and vertical meridians of the cornea, the anterior 
chamber would not uniformly support a perfectly circular 
implant. Furthermore, a detailed and careful evaluation of 
Figure 1 Pentacam image showing a silicone NewColoriris implant in the anterior 
chamber in the (A) right eye, with close apposition with the angle and (B) left eye, 
with asymmetry within the anterior chamber relative to the angle.
Figure  2  Patient  with  blue  NewColoriris  implants  OU.  Note  the  temporal   
dis  placement of the left implant with a decentered light reflex.Clinical Ophthalmology
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the iris must be performed. The eccentricity of the pupillary 
aperture should be assessed. Evaluation of the configuration 
of the iris root by imaging modalities could reveal variants 
such as plateau configuration, which would increase the risk 
of iris chafing. Specific measurement of each individual 
patient’s anatomy may permit custom sizing of the implant 
in the future, with decreased associated risk of complications. 
Nevertheless, if preoperative evaluation suggests a patient 
may be a good candidate for an elective NewColorIris 
implant, this procedure currently has no proven safety record 
and may result in urgent explantation and long-term sight-
threatening sequelae.
Although it is difficult to estimate the extent of compli-
cations as it is unknown how many NewColorIris implants 
have been implanted, review of the literature reveals vision-
threatening complications such as elevated IOP, intraocular 
inflammation, and corneal decompensation. With its   current 
design, implantation should be seriously deliberated and risks 
such as possible surgery for cataracts, elevated IOP, and 
explantation should be extensively discussed with potential 
patients.
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